Toxic Encephalopathy

Michael R Dobbs

doi:10.1055/s-0031-1277989

Seminars in Neurology, Table of Contents

Semin Neurol 2011; 31(2): 184-193
DOI: 10.1055/s-0031-1277989

Toxic Encephalopathy

Michael R. Dobbs¹ ^, ²

¹Department of Neurology, University of Kentucky, College of Medicine, College of Public Health, Lexington, Kentucky
²Department of Preventive Medicine, University of Kentucky, College of Medicine, College of Public Health, Lexington, Kentucky

Abstract

ABSTRACT

Neurotoxic exposures are common. Although there are myriad substances that can cause encephalopathy, this review focuses on common environmental neurotoxins, such as select heavy metals, organic industrial toxins, and pesticides. The central nervous system is susceptible to toxic injury, and many environmental neurotoxins are capable of causing encephalopathy. When a patient presents with toxic encephalopathy, the differential diagnosis is initially broad. The clinical presentation after exposure to a toxin varies in severity among patients. Arriving at the correct diagnosis is often a diagnostic challenge. The importance of taking a good history and performing a comprehensive examination cannot be overemphasized. Neuroimaging and neurophysiologic testing typically play ancillary roles. Confirmatory laboratory testing is available for some toxins. Treatment of most toxic encephalopathies is not supported by clinical trials; additional research is needed in the field.

KEYWORDS

Toxic encephalopathy - neurotoxin - neurotoxicology - encephalopathy

Full Text

References

REFERENCES

1 Hunter D. The Diseases of Occupations. 6th ed. London: Hodderand Stoughton; 1978: 251
2 Anger W K. Workplace exposures. In: Annau Z, ed. Neurobehavioral Toxicology. Baltimore, MD: Johns Hopkins; 1986
3 National Institute for Occupational Safety and Health .National Occupational Hazard Survey, 1972–74. DHEW Publication No. (NIOSH) 78–114. Cincinnati, OH: National Institute for Occupational Health and Safety; 1977
4 Spencer P S, Schaumburg H H. Experimental and Clinical Neurotoxicology. New York: Oxford University Press; 2000
5 Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009
6 Grandjean P, Landrigan P J. Developmental neurotoxicity of industrial chemicals. Lancet. 2006; 368 (9553) 2167-2178
7 Feldman R G. Approach to Diagnosis: Occupational and Environmental Neurotoxicology. Philadelphia: Lippincott-Raven; 1999
8 Bull S. Review of Environmental Chemicals and Neurotoxicity: Focus on Neurological Diseases. Didcot: Centre for Radiation, Chemical and Environmental Hazards; 2007
9 Zuccoli G, Siddiqui N, Cravo I, Bailey A, Gallucci M, Harper C G. Neuroimaging findings in alcohol-related encephalopathies. AJR Am J Roentgenol. 2010; 195 (6) 1378-1384
10 Brust J C. Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review. Int J environ Res Public Health. 2010; 7 (4) 1540-1557
11 Brust J C. Acute neurologic complications of drug and alcohol abuse. J Acquir Immune Defic Syndr. 2002; 31 (Suppl 2) S29-S34
12 Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009. chapters 30–34
13 Chang K H, Han M H, Kim H S, Wie B A, Han M C. Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter lesions. Radiology. 1992; 184 (1) 117-122
14 Merimsky O, Loewenstein A, Chaitchik S. Cortical blindness—a catastrophic side effect of vincristine. Anticancer Drugs. 1992; 3 (4) 371-373
15 Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness. Cancer Chemother Pharmacol. 1992; 29 (4) 329-330
16 Young D C, Mitchell A, Kessler J, Christman J E. Cortical blindness and seizures possibly related to cisplatin, vinblastine, and bleomycin treatment of ovarian dysgerminoma. J Am Osteopath Assoc. 1993; 93 (4) 502-504, 507
17 Filley C M. Toxic leukoencephalopathy. Clin Neuropharmacol. 1999; 22 (5) 249-260
18 Moawad F J, Hartzell J D, Biega T J, Lettieri C J. Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose. South Med J. 2006; 99 (5) 511-514
19 Fugate J E, Claassen D O, Cloft H J, Kallmes D F, Kozak O S, Rabinstein A A. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010; 85 (5) 427-432
20 Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?. Neuroradiology. 2009; 51 (6) 373-383
21 Cooney M J, Bradley W G, Symko S C, Patel S T, Groncy P K. Hypertensive encephalopathy: complication in children treated for myeloproliferative disorders—report of three cases. Radiology. 2000; 214 (3) 711-716
22 Morris E B, Laningham F H, Sandlund J T, Khan R B. Posterior reversible encephalopathy syndrome in children with cancer. Pediatr Blood Cancer. 2007; 48 (2) 152-159
23 Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001; 24 (2) 145-148
24 Pihko H, Tyni T, Virkola K et al.. Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia. J Pediatr. 1993; 123 (5) 718-724
25 Dzudie A, Boissonnat P, Roussoulieres A et al.. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine?: case reports. Transplant Proc. 2009; 41 (2) 716-720
26 Saeed B, Abou-Zor N, Amer Z, Kanani I, Hilal M. Cyclosporin-A induced posterior reversible encephalopathy syndrome. Saudi J Kidney Dis Transpl. 2008; 19 (3) 439-442
27 Cosottini M, Lazzarotti G, Ceravolo R, Michelassi M C, Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol. 2003; 10 (4) 461-462
28 Vahidnia A, van der Voet G B, de Wolff F A. Arsenic neurotoxicity—a review. Hum Exp Toxicol. 2007; 26 (10) 823-832
29 Szlatenyi C S, Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Am J Emerg Med. 1996; 14 (5) 464-466
30 McCunney R J. Diverse manifestations of trichloroethylene. Br J Ind Med. 1988; 45 (2) 122-126
31 Greenberg S A. Acute demyelinating polyneuropathy with arsenic ingestion. Muscle Nerve. 1996; 19 (12) 1611-1613
32 London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin. 2007; 25 (1) 257-276
33 Bartynski W S. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008; 29 (6) 1036-1042
34 Bartynski W S, Boardman J F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007; 28 (7) 1320-1327
35 Oliver L. Laboratory assessment of exposure to neurotoxic agents. In: Dobbs M R, ed. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009: 213-221
36 Schwartz B S, Lee B K, Lee G S et al.. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol. 2001; 153 (5) 453-464
37 Campara P, D'Andrea F, Micciolo R, Savonitto C, Tansella M, Zimmermann-Tansella C. Psychological performance of workers with blood-lead concentration below the current threshold limit value. Int Arch Occup Environ Health. 1984; 53 (3) 233-246
38 Stokes L, Letz R, Gerr F et al.. Neurotoxicity in young adults 20 years after childhood exposure to lead: the Bunker Hill experience. Occup Environ Med. 1998; 55 (8) 507-516
39 Landrigan P J, Todd A C. Lead poisoning. West J Med. 1994; 161 (2) 153-159
40 Saryan L A, Zenz C. Lead and its compounds. In: Saryan L A, Zenz C, eds. Occupational Medicine. 3rd ed. St. Louis, MO: Mosby; 1994: 506-541
41 Karri S K, Saper R B, Kales S N. Lead encephalopathy due to traditional medicines. Curr Drug Saf. 2008; 3 (1) 54-59
42 Canfield R L, Henderson Jr C R, Cory-Slechta D A, Cox C, Jusko T A, Lanphear B P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med. 2003; 348 (16) 1517-1526
43 Perelman S, Hertz-Pannier L, Hassan M, Bourrillon A. Lead encephalopathy mimicking a cerebellar tumor. Acta Paediatr. 1993; 82 (4) 423-425
44 Tüzün M, Tüzün D, Salan A, Hekimoğlu B. Lead encephalopathy: CT and MR findings. J Comput Assist Tomogr. 2002; 26 (3) 479-481
45 Reyes P F, Gonzalez C F, Zalewska M K, Besarab A. Intracranial calcification in adults with chronic lead exposure. AJR Am J Roentgenol. 1986; 146 (2) 267-270
46 American Academy of Pediatrics Committee on Environmental Health . Lead exposure in children: prevention, detection, and management. Pediatrics. 2005; 116 (4) 1036-1046
47 Freeman J W, Couch J R. Prolonged encephalopathy with arsenic poisoning. Neurology. 1978; 28 (8) 853-855
48 Bolla-Wilson K, Bleecker M L. Neuropsychological impairment following inorganic arsenic exposure. J Occup Med. 1987; 29 (6) 500-503
49 Ratnaike R N. Acute and chronic arsenic toxicity. Postgrad Med J. 2003; 79 (933) 391-396
50 Vahidnia A, van der Voet G B, de Wolff F A. Arsenic neurotoxicity—a review. Hum Exp Toxicol. 2007; 26 (10) 823-832
51 London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents. Neurol Clin. 2007; 25 (1) 257-276
52 Matschullat J. Arsenic in the geosphere—a review. Sci Total Environ. 2000; 249 (1-3) 297-312
53 Mukherjee S C, Rahman M M, Chowdhury U K et al.. Neuropathy in arsenic toxicity from groundwater arsenic contamination in West Bengal, India. J Environ. Sci Health A Tox Hazard Subst Environ Eng. 2003; 38 165-183
54 Lund A. Distribution of thallium in the organism and its elimination. Acta Pharmacol Toxicol (Copenh). 1956; 12 (3) 251-259
55 Tromme I, Van Neste D, Dobbelaere F et al.. Skin signs in the diagnosis of thallium poisoning. Br J Dermatol. 1998; 138 (2) 321-325
56 Moeschlin S. Thallium poisoning. Clin Toxicol. 1980; 17 (1) 133-146
57 Mulkey J P, Oehme F W. A review of thallium toxicity. Vet Hum Toxicol. 1993; 35 (5) 445-453
58 Rusyniak D E, Kao L W, Nanagas K A et al.. Dimercaptosuccinic acid and Prussian Blue in the treatment of acute thallium poisoning in rats. J Toxicol Clin Toxicol. 2003; 41 (2) 137-142
59 Chalela J A, Bonillha L, Neyens R, Hays A. Manganese encephalopathy: an under-recognized condition in the intensive care unit. Neurocrit Care. 2010; December 21; (Epub ahead of print)
60 Hauser R A, Zesiewicz T A, Martinez C, Rosemurgy A S, Olanow C W. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. Can J Neurol Sci. 1996; 23 (2) 95-98
61 Butterworth R F, Spahr L, Fontaine S, Layrargues G P. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis. 1995; 10 (4) 259-267
62 Sata F, Araki S, Murata K, Aono H. Behavior of heavy metals in human urine and blood following calcium disodium ethylenediamine tetraacetate injection: observations in metal workers. J Toxicol Environ Health A. 1998; 54 (3) 167-178
63 Herrero Hernandez E, Discalzi G, Valentini C et al.. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. Neurotoxicology. 2006; 27 (3) 333-339
64 Siegler R W, Nierenberg D W, Hickey W F. Fatal poisoning from liquid dimethylmercury: a neuropathologic study. Hum Pathol. 1999; 30 (6) 720-723
65 Lee B K, Lee S H, Lee K M et al.. Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers. Ind Health. 1988; 26 (1) 11-23
66 Lazar R B, Ho S U, Melen O, Daghestani A N. Multifocal central nervous system damage caused by toluene abuse. Neurology. 1983; 33 (10) 1337-1340
67 Yücel M, Takagi M, Walterfang M, Lubman D I. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci Biobehav Rev. 2008; 32 (5) 910-926
68 Bernad P G, Newell S, Spyker D A. Neurotoxicity and behavior abnormalities in a cohort chronically exposed to trichloroethylene. Vet Hum Toxicol. 1987; 29 475
69 Perbellini L, Olivato D, Zedde A, Miglioranzi R. Acute trichloroethylene poisoning by ingestion: clinical and pharmacokinetic aspects. Intensive Care Med. 1991; 17 (4) 234-235
70 Feldman R G, White R F, Currie J N, Travers P H, Lessell S. Long-term follow-up after single toxic exposure to trichloroethylene. Am J Ind Med. 1985; 8 (2) 119-126
71 Lawrence W H, Partyka E K. Chronic dysphagia and trigeminal anesthesia after trichloroethylene exposure. Ann Intern Med. 1981; 95 (6) 710
72 Leandri M, Schizzi R, Scielzo C, Favale E. Electrophysiological evidence of trigeminal root damage after trichloroethylene exposure. Muscle Nerve. 1995; 18 (4) 467-468
73 Szlatenyi C S, Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation. Am J Emerg Med. 1996; 14 (5) 464-466
74 Gash D M, Rutland K, Hudson N L et al.. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2008; 63 (2) 184-192
75 Occupational Safety and Health Administration. Occupational Safety and Health Guideline for Carbon Monoxide. Washington, DC: Department of Labor. Available at: http://www.osha.gov/SLTC/healthguidelines/carbonmonoxide/recognition.html Accessed January 2011
76 Choi I S. Delayed neurologic sequelae in carbon monoxide intoxication. Arch Neurol. 1983; 40 (7) 433-435
77 Min S K. A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta Psychiatr Scand. 1986; 73 (1) 80-86
78 Rusyniak D E. Pearls and pitfalls in the approach to patients with neurotoxic syndromes. Semin Neurol. 2001; 21 (4) 407-416
79 Hardy K R, Thom S R. Pathophysiology and treatment of carbon monoxide poisoning. J Toxicol Clin Toxicol. 1994; 32 (6) 613-629
80 Gorman D, Drewry A, Huang Y L, Sames C. The clinical toxicology of carbon monoxide. Toxicology. 2003; 187 (1) 25-38
81 Blumenthal I. Carbon monoxide poisoning. J R Soc Med. 2001; 94 (6) 270-272
82 Tapeantong T, Poungvarin N. Delayed encephalopathy and cognitive sequelae after acute carbon monoxide poisoning: report of a case and review of the literature. J Med Assoc Thai. 2009; 92 (10) 1374-1379
83 National Research Council of The National Academies .Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press; 2007

Michael R DobbsM.D.

740 South Limestone Street

Wing D Kentucky Clinic L-412, Lexington, KY 40536

Email: mrdobb0@email.uky.edu